Mark Lucy

[💙😇 @BatPitt]

$NVAX --> $120 +
$IBRX --> $50 +

[PK_Fund @PK_Fund]

$IBRX Between now and 12/31/26 IBRX will have 8 different medical presentations: Piper Sandler; Euro Society for Medical Oncology; Society for Immunotherapy; Society of Neuro Oncology; Masters in Therapeutic Oncology; Jefferies Global Healthcare; American Society of Hematology and UBS Global Biopharma. Some sort of news should precede all of this.

[Dr. Pat Soon-Shiong @DrPatrick]

Will discuss status of these trials at my fireside chat next week

[Brandon Rosewag @SAAS1975]

$IBRX between $9.50 - $10 loading zone! It will break $12 soon

[ImmunityBio, Inc. @ImmunityBio]

@DrPatrick will join @Piper_Sandler Virtual Oncology Symposium on Oct 16, 1PM ET for a fireside chat on ImmunityBio’s clinical progress and vision for cancer immunotherapy.

https://t.co/VwckKZkojR

Contact Piper Sandler for information about attending the symposium and accessing session recordings.

[Dr. Pat Soon-Shiong @DrPatrick]

So exciting that European clinicians have insights into the immunotherapy approach to address sepsis.

Sepsis affects 50 million people worldwide. Met with the leadership of ImmunoSEP https://t.co/wHjiz0VqQn and exchanging information to explore a sepsis trial in Europe.

ALC matters.

IL-15 improves survival as presented in this 2010 paper by Dr. Richard Hotchkiss.

[Dr. Pat Soon-Shiong @DrPatrick]

Imagine if a doctor could in real time integrate the care of a cancer patient with precision by seamlessly using all the tools available such as modernized imaging, immunotherapy, chemotherapy and radiation. That day has arrived thanks to Aetna CVS  and our amazing tech/ AI team at NantIQ (another NantWorks company).

Eviti -EVIdence based Treatment Integration for best outcomes, a decade in the making at NantIQ.

Thank you @Aetna and @cvspharmacy for your leadership in innovation in healthcare as we enter the AI era and 21st century precision cancer care. Immunotherapy 2.0

Next is to enable both doctors and patients learn about the most advanced clinical trials with the best outcome - Trial Match!

https://t.co/W9G2a4OWn0

[💙😇 @BatPitt]

#ANKTIVA vs cancer, Lymphopenia
$IBRX

[IBRX @__IBRX_]

Did you know? $IBRX

[Olivia @oliviatrading_6]

Honestly, I’m not looking for a short squeeze or a parabolic move in $IBRX. I want slow, organic share-price growth to $80+. Do that, and the rest takes care of itself.

[GainzAlgo @gainzalgo]

$IBRX is trending again, closing in on 31K watchers as momentum continues to build.

[Lysander @Lysander887l]

$IBRX Dr. Patrick said he would need to "obtain clearance" just to release video of him at talking at NIH/NIC.

My goodness, cannot fathom the amount of what else must be under wraps.

I bet some of that 30 million volume Friday they know more than we do.

[Dr. Pat Soon-Shiong @DrPatrick]

Best of wishes Michael and Congratulations .

There are millions of patients with cancer worldwide who are in complete remission. The next frontier is to develop therapies strengthening the immune system to prevent recurrence in these over 15 million patients in the USA alone, and drive long term durable freedom from cancer to win the war. Incremental short term duration of response should no longer be an acceptable outcome.

The therapies to address and maintain cancer free status are now here……..the orchestration of the immune system, the identification of tumor DNA in the peripheral blood, the easy measurement of the NK and T cell levels in the peripheral blood count, the sophistication of next gen PET/ MRI/ CT scans, the ability to grow and store activated NK cells, the ability to identify tumor educated T cells, the new knowledge of camelid derived heavy chain single domain antibodies and the ability to precisely target radioactive ligands, to precisely target CART and CarNK and CAR-iNKT cells. These immunotherapy advances are all here today and in various stages of clinical trials. The oncology community will enter this next generation of paradigm change. The need to establish these diagnostic and therapeutic combinations as IMMUNOTHERAPY 2.0 is both urgent and exhilarating.

This was the subject of my one hour talk with NIH and NCI and the decade of collaboration with Jeffrey Schlom and James Gulley to develop a cancer vaccine. Hope to release the talk once I receive the video recording and obtain clearance to make it public. We are closer than ever.

[Bullish @bullishbruk]

@MichaelRCaputo Congratulations, Michael. Your appointment to the President’s Cancer Panel is well earned. The cancer is gone, but rebuilding what treatment took is not over. Survivors on that panel can speak to barriers the rest of us only live through.
Chemo and radiation clear disease and often leave the immune system depleted. Many find immunotherapy the next must, not an add-on. $IBRX ANKTIVA, an IL-15 superagonist, activates natural killer and T cells after conventional treatment.
Reach out to @LoriMills4CA42 @GretchMick @Brandon_r_clark SpecialK, and others who have lived this. Their firsthand experience is the clearest way to understand what it can mean for rebuilding. Glad you are in this seat. Praying continued strength for you and everyone still in the fight. @DrPatrick

[Dr. Tomislav Marinovic @DrTomsLens]

$IBRX shorts, how’s the weather in hell?

[Katrina Helle @KatrinaHelle]

$IBRX talking about short covering… my opinion is that they will start covering above $13 and hope that is true because we need the fuel from $13 to $45+

[Olivia @oliviatrading_6]

$IBRX $15 today. !! 🚀🚀🚀

[Brandon Rosewag @SAAS1975]

$IBRX WE HAVEN’T EVEN STARTED
Now read that again.
🚀🚀🚀

[David Din, CFA @DavidDin]

$IBRX

Danny, you make me feel lucky.

[Katrina Helle @KatrinaHelle]

$IBRX at this level IBRX will be added to the Russell 1000, and many funds will need to buy IBRX.